Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussion focused on the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
Real-World Experiences and Evidence
The discussion highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Stewart, MD, summarized the key takeaways from the discussion.
He is a professor and the chairman emeritus of ophthalmology at Mayo Clinic in Jacksonville, Florida, and the Knights Templar Eye Foundation Inc. Professor in Ophthalmology Research.
Case Study
Stewart described an 83-year-old woman with diabetic macular edema (DME) who had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Author's summary: Anti-VEGF agents improve retinal disease treatment.
More News
- Record Job Cuts at Amazon and UPS. AI and Reorganization Changing the Face of Logistics
- 'Dead and Breakfast': Dark Comedy Theatre Show Takes On The Apocalypse
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- VisitMalta Wins Gold At US Travel Awards For Second Year In A Row
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Over 2,700 People Denied Maltese Citizenship In Past Five Years
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Coats Completes Acquisition of OrthoLite | SGB Media Online
- Chipotle’s Stock Plunges 18% On Lowered Guidance